Introduction
Delameg IV Infusion 300 mg/vial is a broad-spectrum fluoroquinolone antibiotic used to treat various bacterial infections. It is effective against both Gram-positive and Gram-negative bacteria, including those resistant to other antibiotics. Delameg IV Infusion 300 mg/vial is used to manage acute bacterial infections and offers an option for patients with infections that do not respond to other treatments.
Uses
Delameg IV Infusion 300 mg/vial is indicated for the treatment of:
- Acute bacterial skin and skin structure infections (ABSSSI)
- Complicated urinary tract infections (cUTI)
- Chronic bacterial infections that may not respond to first-line antibiotics
| Brand Name | Delameg |
|---|---|
| Type | IV Infusion |
| Weight | 300 mg/vial |
| Generic | Delafloxacin |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Mechanism of Action
Delameg IV Infusion 300 mg/vial works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and transcription. This inhibition prevents the bacteria from reproducing and repairing their DNA, leading to bacterial cell death.
How Long Does It Take to Work?
Patients may begin to see improvements in symptoms within 48-72 hours of starting delafloxacin. The full therapeutic effect may take up to a week, depending on the severity of the infection and individual patient response.
Absorption
Delameg IV Infusion 300 mg/vial is well-absorbed after oral administration, with peak plasma concentrations typically occurring within 1-2 hours. The drug has good oral bioavailability, meaning a significant portion of the dose is absorbed into systemic circulation.
Route of Elimination
Delameg IV Infusion 300 mg/vial is primarily metabolized in the liver, with a portion excreted unchanged in the urine. The drug is eliminated from the body mainly through the kidneys, with a smaller fraction eliminated in the feces.
Dosage
Route of administration: Intravenous (IV) Injection| Indications | Dosage and Route of Administration | Total Duration (days) |
| Acute Bacterial Skin and Skin Structure Infections (ABSSSI) | 300 mg of Delafloxacin Injection every 12 hours over 60 minutes by intravenous infusion | 5 to 14 |
| Community-Acquired Bacterial Pneumonia (CABP) | 5 to 10 |
Hepatic Impairment: No dosage adjustment is necessary for Delaflox (Delafloxacin) in patients with hepatic impairment.
Renal Impairment: Dosage adjustment is required for patients with severe renal impairment (eGFR 15-29 mL/min/1.73m2). In patients with severe renal impairment or ESRD (eGFR of < 15 mL/min/1.73 m2), accumulation of the intravenous vehicle, sulfobutylether-β-cyclodextrin (SBECD) occurs. Serum creatinine levels should be carefully monitored in patients in such case. If serum creatinine level increases, consider switching to oral Delafloxacin. Discontinue Delafloxacin if eGFR decreases to < 15 mL/min/1.73 m2.
The typical dosage for delafloxacin is:
- For acute bacterial skin infections: 300 mg orally every 12 hours for 5-14 days, depending on the severity of the infection.
- For complicated urinary tract infections: 450 mg orally every 12 hours for 7-14 days.
Administration
Delameg IV Infusion 300 mg/vial should be taken orally, with or without food. Tablets should be swallowed whole with a glass of water. Consistent dosing times are important to maintain therapeutic drug levels.
Side Effects
Common side effects of delafloxacin include:
- Nausea
- Diarrhea
- Headache
- Dizziness
- Abdominal pain
Toxicity
In cases of overdose or severe adverse reactions, symptoms may include severe gastrointestinal distress, seizures, or cardiac issues. Immediate medical intervention is required to manage toxicity and provide supportive care.
Precautions
- Monitor patients for signs of tendonitis or tendon rupture, especially in those over 60 or on corticosteroids. - Use with caution in patients with a history of seizures or other central nervous system disorders. - Regularly monitor liver function in long-term or high-dose therapy.
Interaction
Delameg IV Infusion 300 mg/vial may interact with other medications, including:
- Antacids or products containing calcium, magnesium, or aluminum, which may reduce delafloxacin absorption.
- Warfarin, which may increase the risk of bleeding.
- Other drugs that affect liver enzymes, altering delafloxacin metabolism.
Disease Interaction
- Caution is advised in patients with liver disease, as delafloxacin is metabolized hepatically. - Adjustments may be needed for patients with renal impairment.
Drug Interaction
Delameg IV Infusion 300 mg/vial may interact with medications that alter gastrointestinal pH or affect liver enzymes. It's essential to inform healthcare providers of all concurrent medications to avoid potential interactions.
Food Interactions
Food does not significantly affect the absorption of delafloxacin. The medication can be taken with or without food.
Pregnancy Use
Delameg IV Infusion 300 mg/vial is classified as a Category C drug for pregnancy, meaning risk cannot be ruled out. It should be used during pregnancy only if the potential benefits outweigh the risks.
Lactation Use
It is not known whether delafloxacin is excreted in breast milk. Due to potential risks to the infant, breastfeeding is not recommended during treatment with delafloxacin.
Acute Overdose
Acute overdose may result in severe gastrointestinal symptoms, neurological effects, or cardiac issues. Immediate medical treatment is required to manage symptoms and provide appropriate care.
Contraindication
Delameg IV Infusion 300 mg/vial is contraindicated in:
- Patients with a known hypersensitivity to delafloxacin or other fluoroquinolones.
- Pregnant or breastfeeding women due to potential risks to the fetus or infant.
Use Direction
Take the prescribed dose of delafloxacin orally, with or without food. Do not exceed the recommended dose. Follow the treatment regimen exactly as directed by your healthcare provider.
Storage Conditions
Store delafloxacin at room temperature, away from moisture and heat. Keep the medication in its original packaging to protect it from light and ensure it is out of reach of children.
Volume of Distribution
The volume of distribution for delafloxacin is approximately 40-50 L, indicating its extensive distribution throughout body tissues.
Half Life
The elimination half-life of delafloxacin is approximately 8-10 hours, allowing for twice-daily dosing.
Clearance
Delameg IV Infusion 300 mg/vial is cleared primarily through renal excretion, with a clearance rate of approximately 20-30 L/h. This reflects its efficient elimination from the body through the kidneys.
See in details version Delameg IV Infusion 300 mg/vial also Delameg IV Infusion 300 mg/vial in bangla
Some Frequently Asked Questions About Delameg IV Infusion 300 mg/vial
